Your browser doesn't support javascript.
loading
Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population.
Asayama, Kei; Thijs, Lutgarde; Li, Yan; Gu, Yu-Mei; Hara, Azusa; Liu, Yan-Ping; Zhang, Zhenyu; Wei, Fang-Fei; Lujambio, Inés; Mena, Luis J; Boggia, José; Hansen, Tine W; Björklund-Bodegård, Kristina; Nomura, Kyoko; Ohkubo, Takayoshi; Jeppesen, Jørgen; Torp-Pedersen, Christian; Dolan, Eamon; Stolarz-Skrzypek, Katarzyna; Malyutina, Sofia; Casiglia, Edoardo; Nikitin, Yuri; Lind, Lars; Luzardo, Leonella; Kawecka-Jaszcz, Kalina; Sandoya, Edgardo; Filipovský, Jan; Maestre, Gladys E; Wang, Jiguang; Imai, Yutaka; Franklin, Stanley S; O'Brien, Eoin; Staessen, Jan A.
Afiliação
  • Asayama K; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Thijs L; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Li Y; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Gu YM; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Hara A; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Liu YP; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Zhang Z; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Wei FF; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Lujambio I; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Mena LJ; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Boggia J; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Hansen TW; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Björklund-Bodegård K; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Nomura K; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Ohkubo T; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Jeppesen J; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Torp-Pedersen C; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Dolan E; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Stolarz-Skrzypek K; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Malyutina S; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Casiglia E; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Nikitin Y; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Lind L; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Luzardo L; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Kawecka-Jaszcz K; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Sandoya E; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Filipovský J; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Maestre GE; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Wang J; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Imai Y; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Franklin SS; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • O'Brien E; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
  • Staessen JA; From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (K.A., L.T., Y.-M.G., A.H., Y.-P.L., Z.Z., F.-F.W., J.A.S.); Department of Planning for Drug Development and Clinic
Hypertension ; 64(5): 935-42, 2014 Nov.
Article em En | MEDLINE | ID: mdl-25135185
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Monitorização Ambulatorial da Pressão Arterial / Hipertensão Mascarada / Hipertensão do Jaleco Branco Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Monitorização Ambulatorial da Pressão Arterial / Hipertensão Mascarada / Hipertensão do Jaleco Branco Idioma: En Ano de publicação: 2014 Tipo de documento: Article